Cargando…
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
ABSTRACT: The terminal complement protein (C5) inhibitor eculizumab (Soliris(®)) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) ser...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183484/ https://www.ncbi.nlm.nih.gov/pubmed/32266705 http://dx.doi.org/10.1007/s40265-020-01297-w |